Skip to main content

Table 2 Cox regression analysis of hazard ratio on NSCLC patients with diabetes mellitus

From: MiR-1231 decrease the risk of cancer-related mortality in patients combined with non-small cell lung cancer and diabetes mellitus

Variation Non-adjustment Model 1
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Gender, male vs. female 1.68 [1.04, 2.73] 0.035*
Age (year), ≥ 60 vs. < 60 1.20 [0.76, 1.89] 0.443
BMI, ≥ 23.9 kg/m2 vs. < 23.9 kg/m2 0.66 [0.43, 1.02] 0.059 0.68 [0.44, 1.05] 0.08
Serum CEA level, > 3.9 ng/mL vs. ≤ 3.9 ng/mL 1.43 [0.93, 2.19] 0.106 1.35 [0.88, 2.09] 0.172
Serum CRP level, > 9.49 μmol/L vs. ≤ 9.49 μmol/L 2.18 [1.41, 3.38] < 0.001*** 2.08 [1.34, 3.23] 0.001**
Albumin level, ≤ 40.01 g/L vs. > 40.01 g/L 2.67 [1.73, 4.13] < 0.001*** 2.53 [1.55, 4.11] < 0.001***
Neutrophils count, > 4.68 × 109/L vs. ≤ 4.68 × 109/L 1.77 [1.15, 2.73] 0.009** 1.61 [1.01, 2.57] 0.046***
Lymphocytes count, > 1.68 × 109/L vs. ≤ 1.68 × 109/L 0.70 [0.46, 1.08] 0.104 0.70 [0.46, 1.08] 0.109
Hemoglobin level, > 133 g/L vs. ≤ 133 g/L 0.70 [0.45, 1.07] 0.095 0.60 [0.39, 0.94] 0.024**
Platelet count, > 228.5 × 109/L vs. ≤ 228.5 × 109/L 1.42 [0.92, 2.18] 0.109 1.53 [0.99, 2.36] 0.057
PNI score, > 49.22 vs. ≤ 49.22 0.40 [0.26, 0.62] < 0.001*** 0.42 [0.27, 0.66] < 0.001***
NLR, > 2.9 vs. ≤ 2.9 1.85 [1.20, 2.85] 0.005** 1.71 [1.09, 2.67] 0.019*
Pathologic type, Adenocarcinoma vs. others 1.01 [0.66, 1.54] 0.975 1.13 [0.72, 1.76] 0.601
Metastasis, Yes vs. No 1.66 [1.06, 2.60] 0.026* 1.70 [1.09, 2.65] 0.02*
Stage of NSCLC, IV, III vs. II and I 2.01 [1.12, 3.62] 0.019* 1.86 [1.01, 3.42] 0.048*
Surgery, Yes vs. No 0.27 [0.17, 0.45] < 0.001*** 0.26 [0.15, 0.43] < 0.001***
Therapy of radiation, Yes vs. No 1.36 [0.88, 2.09] 0.163 1.34 [0.85, 2.11] 0.21
Application of platinum, Yes vs. No 0.27 [0.08, 0.87] 0.028* 0.32 [0.10, 1.06] 0.062
Target therapy, Yes vs. No 1.03 [0.65, 1.62] 0.903 1.09 [0.69, 1.72] 0.724
Application of TKI, Yes vs. No 1.12 [0.69, 1.81] 0.644 1.15 [0.71, 1.87] 0.567
Application of VEGF inhibitor, Yes vs. No 0.81 [0.40, 1.61] 0.539 0.74 [0.37, 1.48] 0.389
Chemotherapy, AP vs. others 0.83 [0.54, 1.28] 0.407 0.91 [0.59, 1.42] 0.685
Smoking, Yes vs. No 1.45 [0.94, 2.24] 0.095 1.02 [0.56, 1.87] 0.936
Hypertension, Yes vs. No 0.96 [0.62, 1.49] 0.854 0.88 [0.56, 1.39] 0.59
Hyperlipemia, Yes vs. No 0.61 [0.34, 1.09] 0.096 0.61 [0.34, 1.08] 0.089
Heart failure, Yes vs. No 12.63 [2.84, 56.17] 0.001** 10.67 [2.38, 47.88] 0.002**
ACS, Yes vs. No 0.73 [0.18, 2.96] 0.656 0.82 [0.20, 3.37] 0.787
KPS score, > 80 vs. ≤ 80 0.27 [0.17, 0.43] < 0.001*** 0.27 [0.17, 0.43] < 0.001***
miR-1231, > 1.78 vs. ≤ 1.78 0.37 [0.23, 0.57] < 0.001 0.36 [0.23, 0.57] < 0.001***
  1. Model 1: Adjusted by age and gender
  2. HR, hazard risk; BMI, Body Mass Index; CRP, C-reactive protein; PNI, neutrophil lymphocyte ratio; NLR, neutrophil lymphocyte ratio; NSCLC, non-small-cell lung cancer; TKI, Tyrosine Kinase Inhibitor; VEGF, vascular endothelial growth factor; KPS, Karnofsky Performance Status; ACS, acute coronary syndrome. ***P < 0.001, **P < 0.01, *P < 0.05